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OBJECTIVE — Tostudymortalityinrelationtofastingplasmaglucose(FPG)and2-hplasma
glucose levels within the normoglycemic range.
RESEARCH DESIGN AND METHODS — Data from 19 European cohorts comprising
12,566 men and 10,874 women who had FPG 6.1 mmol/l and 2-h plasma glucose 7.8
mmol/l at baseline examination were analyzed. Multivariate-adjusted hazard ratios (HRs) and
95% CIs for deaths from cardiovascular disease (CVD), non-CVD, and all causes were estimated
for individuals whose 2-h plasma glucose  FPG (group II) compared with those whose 2-h
plasma glucose  FPG (group I).
RESULTS — A total of 827 (246) CVD and 611 (351) non-CVD and 1,438 (597) all-cause
deaths occurred in men (women). Group II was older and had higher BMI, blood pressure, and
fasting insulin than group I. The multivariate-adjusted HRs (95% CIs) for CVD, non-CVD, and
all-cause mortality were 1.22 (1.05–1.41), 1.09 (0.92–1.29), and 1.16 (1.04–1.30) in men
and 1.40 (1.03–1.89), 0.99 (0.79–1.25), and 1.13 (0.94–1.35) in women, respectively, for
group II as compared with group I. HRs were 1.25 (1.05–1.50), 1.09 (0.89–1.34), and 1.18
(1.03–1.35) in men and 1.60 (1.03–2.48), 1.05 (0.78–1.42), and 1.18 (0.93–1.51) in women,
respectively, after additional adjustment for fasting insulin in a subgroup of individuals.
CONCLUSIONS — In individuals with both FPG and 2-h plasma glucose within the nor-
moglycemicrange,high2-hplasmaglucosewasassociatedwithinsulinresistanceandincreased
CVD mortality.
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I
t is well known that type 2 diabetes
(1,2) and nondiabetic hyperglycemia
such as impaired glucose tolerance are
risk factors for cardiovascular disease
(CVD) mortality (3–5). The relations of
fasting plasma glucose (FPG) and 2-h
plasma glucose with CVD mortality and
morbidity have been extensively investi-
gated during the last few decades (6–9).
Evidence has shown that 2-h plasma glu-
cose is a stronger risk predictor than FPG
for incident coronary heart disease (6)
andCVDmortality(7),butlittleisknown
about the impact of FPG versus 2-h
plasma glucose in the normoglycemic
range. It has been suggested that individ-
uals with normoglycemia, whose 2-h
plasma glucose did not return to the FPG
levelsduringanoralglucosetolerancetest
(OGTT) had a signiﬁcantly higher risk of
developing type 2 diabetes (10) and a
worse cardiovascular risk factor proﬁle
(11) than individuals whose 2-h plasma
glucose returned to the FPG levels. In
thecurrentstudy,basedonthedataofthe
Diabetes Epidemiology: Collaborative
Analysis of Diagnostic Criteria in Europe
(DECODE) study, we compared CVD
mortality in individuals whose 2-h
plasma glucose was higher than FPG with
those whose 2-h plasma glucose was
equal to or lower than FPG.
RESEARCH DESIGN AND
METHODS— The methods to recruit
participants for the DECODE cohorts
have been described previously (6,12–
14). In brief, the database was collected
from researchers who had performed ep-
idemiological studies using a standard
OGTT in Europe. Data of individuals
fromparticipatingstudycentersweresent
to the Diabetes Prevention Unit, Depart-
mentofChronicDiseasePreventionofthe
National Institute for Health and Welfare
in Helsinki, Finland, for analyses. Each
studyhadbeenapprovedbythelocaleth-
ics committees, and the ethics committee
of the National Institute for Health and
Welfare approved the data analysis. In
this article, only the cohorts with pro-
spective data on cause-speciﬁc mortality
and with all required covariates of BMI,
blood pressure, total cholesterol, and
smoking status were included.
Subjects with known diabetes and
those classiﬁed as having newly diag-
nosed diabetes and pre-diabetes accord-
ing to the World Health Organization/
International Diabetes Federation 2006
criteria (15) were excluded from the cur-
rentstudy.Thus,thecurrentdataanalysis
is restricted to normoglycemic individu-
als whose FPG 6.1 mmol/l and 2-h
plasma glucose 7.8 mmol/l (15), com-
prising 12,566 (53.6% of all participants)
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25–90 years from 19 European cohorts.
The maximum duration of follow-up
ranged from 4.8 to 36.8 years among dif-
ferent cohorts with a median follow-up of
9.0 years. According to FPG and 2-h
plasma glucose levels, these individuals
were further divided into two groups. In
group I, an individual’s 2-h plasma glu-
cose concentration was equal to or less
than his or her FPG, whereas in group II,
2-hplasmaglucosewasgreaterthanFPG.
BMI was deﬁned as the individual’s
body weight in kilograms divided by the
square of height in meters. An individual
with a history of hypertension diagnosed
by a physician or having systolic blood
pressure (SBP) 140 mmHg and/or dia-
stolic blood pressure (DBP) 90 mmHg
was classiﬁed as having hypertension
(16). Smoking status was classiﬁed as
current smoker, former smoker, or
nonsmoker.
Deﬁnition of fatal events
Vital status was recorded for each of the
subjects attending the baseline examina-
tioninallofthestudies.Subjectswhohad
emigratedandforwhomvitalstatuscould
notbeconﬁrmedweretreatedascensored
at the time of emigration. Causes of death
werecodedaccordingtoICD-9(ICD-10).
Total CVD death was deﬁned as ICD
codes 401–448 (I10–I79); all other
deaths were classiﬁed as non-CVD.
Statistical methods
A general linear model of univariate
ANOVA was used to estimate means ad-
justed for age and cohort. The 
2 test was
used to test the difference in proportions
between groups. Considering the differ-
enceinlaboratoryassaysoffastinginsulin
betweencohorts,wedeterminedazscore
(z[]/)transformationforfasting
insulin for each cohort before the data
were pooled together. The assumption of
the proportionality was examined using
log minus log survival plots for each cat-
egorical variable. None of these indicated
departure from the assumption of the
proportionality of hazards. Cox propor-
tional hazards analysis was used to calcu-
latehazardratios(HRs)andtheir95%CIs
for CVD, non-CVD, and all-cause mortal-
ity. The models were adjusted for age,
cohort, FPG, BMI, total cholesterol,
smoking status, hypertension status, and
fasting insulin. The difference between
the 2-h plasma glucose and the FPG (2-h
plasma glucose  FPG) as a continuous
variable was also ﬁtted in a separate mul-
tivariable model to examine whether the
relationship was linear. In addition, to
check whether the “return of the 2-h
plasma glucose to the FPG level” was de-
termined by the FPG levels, the compari-
son of group II versus group I was further
made in two FPG subgroups: FPG 5.6
mmol/l and 5.6 mmol/l  FPG 6.1
Table 1—Baseline characteristics of study cohorts and number of deaths from CVD, non-CVD, and all causes in individuals with FPG <6.1
mmol/l and 2-h plasma glucose <7.8 mmol/l
Countries and
studies
n
(men/women) Age (years) FPG (mmol/l)*
2-h PG
(mmol/l)*
No. of deaths (men/women)
Follow-up years CVD Non-CVD All cause
Demark
Glostrup 461/544 54 (39–70) 5.4 (5.4–5.5) 5.9 (5.8–5.9) 98/61 68/47 166/108 17.1 (15.6, 19.1)
Finland
East-West 187/— 76 (70–90) 5.2 (5.1–5.3) 5.6 (5.5–5.8) 69/— 34/— 103/— 8.8 (4.6, 14.8)
FINRISK 1987 985/1,100 53 (44–64) 5.1 (5.1–5.1) 5.6 (5.5–5.6) 125/58 84/60 209/118 19.8 (19.8, 19.9)
FINRISK 1992 566/814 54 (44–64) 5.3 (5.2–5.3) 5.5 (5.4–5.5) 28/11 16/36 44/47 14.9 (14.8, 14.9)
FINRISK 2002 842/1,323 57 (45–74) 5.5 (5.5–5.5) 5.5 (5.5–5.6) 5/3 9/7 14/10 4.8 (4.8, 4.9)
Helsinki policemen 687/— 45 (31–69) 5.6 (5.5–5.6) 5.4 (5.3–5.5) 199/— 108/— 307/— 32.9 (21.8, 36.2)
Oulu 93/172 55 (55–55) 5.4 (5.4–5.5) 6.1 (5.9–6.2) 1/2 9/6 10/8 10.0 (10.0, 10.1)
Vantaa 147/188 65 (64–66) 5.3 (5.2–5.3) 6.2 (6.1–6.3) 16/6 3/3 19/9 13.3 (13.1, 13.6)
Italy
Cremona Study 618/794 57 (40–88) 5.0 (5.0–5.0) 4.9 (4.9–5.0) 54/47 66/42 120/89 15.1 (14.6, 15.6)
Poland
MONICA 98/116 57 (44–73) 5.3 (5.2–5.3) 5.7 (5.5–5.8) 9/1 3/2 12/3 6.5 (6.4, 6.5)
Sweden
Malmö —/834 54 (48–57) 5.6 (5.6–5.7) 6.6 (6.5–6.7) —/11 —/31 —/42 14.6 (13.7, 17.8)
MONICA 1,315/1,365 46 (25–74) 5.1 (5.1–5.1) 5.2 (5.2–5.3) 31/11 22/21 53/32 12.6 (2.6, 16.6)
ULSAM 651/— 71 (70–74) 5.1 (5.1–5.1) 5.8 (5.7–5.9) 62/— 65/— 127/— 10.2 (9.1, 11.1)
The Netherlands
Hoorn Study 798/975 61 (49–77) 5.3 (5.2–5.3) 5.0 (4.9–5.0) 41/19 41/31 82/50 8.9 (8.3, 9.3)
Zutphen Study 289/— 76 (70–90) 5.3 (5.2–5.3) 5.1 (5.0–5.7) 29/— 13/— 42/— 4.7 (4.6, 4.8)
U.K.
ELY 262/411 53 (40–67) 5.5 (5.5–5.5) 5.6 (5.5–5.7) 11/3 13/17 24/20 14.6 (13.9, 15.4)
Goodinge Study 214/346 52 (39–76) 5.7 (5.6–5.7) 5.5 (5.4–5.6) 10/7 7/14 17/21 8.7 (8.4, 9.0)
Newcastle Heart
Project 224/254 53 (30–76) 5.5 (5.5–5.5) 5.5 (5.4–5.6) 13/2 11/12 24/14 8.9 (8.5, 9.3)
Whitehall II study 4,129/1,638 49 (39–62) 5.1 (5.1–5.2) 5.2 (5.2–5.3) 26/4 39/22 65/26 5.9 (5.6, 6.1)
Total 12,566/10,874 54 (25–90) 5.3 (5.2–5.3) 5.4 (5.4–5.4) 827/246 611/351 1,438/597 9.0 (5.8, 14.9)
Data are n, mean (range), or median (25th, 75th percentiles) unless otherwise indicated. *Age-adjusted means (95% CIs). MONICA, Monitoring of Trends and
Determinants in Cardiovascular Disease; PG, plasma glucose; ULSAM, Uppsala Longitudinal Study of Adult Men.
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derived from the same multivariate Cox
proportional hazards analysis. Statistical
analyses were performed using SPSS for
Windows (version 15.0; SPSS Inc. Chi-
cago, IL). P  0.05 (two-tailed) was con-
sidered statistically signiﬁcant.
RESULTS— A total of 1,438 deaths in
men and 597 in women occurred during
the follow-up. Among these, 827 men
and 246 women died of CVD (Table 1).
Mortality from CVD and all causes was
higher in group II than in group I in both
men and women (P  0.001 for all com-
parisons) (Table 2). People in group II
were older and had signiﬁcantly higher
levels of BMI, blood pressure, and fasting
insulin than individuals in group I for
both men and women (P  0.001 for all
comparisons) (Table 2).
The multivariate adjusted HR for
CVD death was signiﬁcantly higher for
group II than for group I for both sexes
but did not differ between the two groups
fornon-CVDdeaths(Table3).Theresults
were not altered after adjustment for fast-
ing insulin in a subgroup of the study
population (9,978 men and 7,350
women) (Table 3). Further analysis in the
two FPG subgroups did not change the
results either (supplementary Table,
available in an online appendix at http://
care.diabetesjournals.org/cgi/content/
full/dc09-2328/DC1). HRs (95% CI) for
theCVDmortalitywere1.27(1.08–1.48)
inindividualswithFPG5.6mmol/land
1.26 (1.00–1.59) in those with FPG 5.6–
6.1 mmol/l, for group II compared with
group I. The cumulative survival proﬁle
was better in group I than in group II for
CVD mortality, but the difference for
non-CVD mortality was not statistically
signiﬁcant (Fig. 1).
HRs (95% CIs) corresponding to a
1-unit increase in the difference between
the 2-h plasma glucose and the FPG con-
centrations (2-h plasma glucose-FPG)
were 1.09 (1.03–1.16) for the CVD
deaths, 1.04 (0.98–1.12) for non-CVD
deaths, and 1.07 (1.02–1.12) for all-
cause deaths in men and 1.09 (0.97–
1.23), 1.00 (0.90–1.10), and 1.04
(0.96–1.12) in women, respectively.
The analysis was adjusted for age, co-
hort,FPG,BMI,totalcholesterol,smok-
ing, and hypertension status.
CONCLUSIONS — In individuals
with both FPG and 2-h plasma glucose
within the normoglycemic range, ele-
vated 2-h plasma glucose conveyed in-
creasedmortalityriskfromCVDbutnot
from non-CVD.
Previous studies have shown that el-
evated 2-h plasma glucose was a stronger
CVD risk predictor than elevated FPG
Table 2—Baseline characteristics of participants and mortality from CVD, non-CVD, and all causes according to FPG and 2-h plasma glucose
categories
Men Women
Group I: 2-h
PG  FPG
Group II: 2-h
PG  FPG
Group I: 2-h
PG  FPG
Group II: 2-h
PG  FPG
n (%) 6,663 (53.0) 5,903 (47.0) 4,096 (37.7) 6,778 (62.3)
Age (years) 52 (52–53)† 55 (55–55) 52 (52–53)† 54 (54–54)
BMI (kg/m
2) 25.5 (25.4–25.6)† 25.9 (25.8–26.0) 25.4 (25.3–25.6)† 26.0 (25.9–26.1)
FPG (mmol/l) 5.3 (5.3–5.3) 5.2 (5.2–5.2) 5.2 (5.2–5.3) 5.2 (5.2–5.2)
2-h PG (mmol/l) 4.3 (4.3–4.4)† 6.2 (6.2–6.3) 4.5 (4.5–4.5)† 6.3 (6.3–6.3)
Fasting insulin (pmol/l)* 0.03 (0.06 to 0)† 0.08 (0.05–0.11) 0.11 (0.14 to 0.08)† 0.04 (0.01–0.07)
Total cholesterol (mmol/l) 6.2 (6.2–6.3) 6.2 (6.2–6.2) 6.2 (6.2–6.3) 6.3 (6.2–6.3)
Blood pressure (mmHg)
Systolic 131 (130–131) 133 (133–134) 128 (128–129) 132 (132–133)
Diastolic 81 (81–82) 83 (83–83) 78 (77–78) 80 (80–80)
Current smoking (%) 23.4† 20.2 23.9† 17.9
Hypertension (%) 35.6† 47.1 34.3† 45.2
Mortality per 1,000 person years (n)
CVD 5.4 (378)† 7.4 (449) 1.4 (59)† 2.3 (187)
Non-CVD 4.3 (299) 5.1 (312) 2.8 (122) 2.9 (229)
All-cause 9.7 (677)† 12.5 (761) 4.2 (181)† 5.2 (416)
Data are n (%) or age- and study-adjusted means (95% CIs). *9,978 men and 7,350 women with z score transformation. †P  0.001 for different between groups
in men and women.
Table 3—HRs (95% CIs) for death from CVD, non-CVD, and all causes for group II compared
with group I
Model 1 Model 2 Model 3
Men
n 12,566 12,566 9,978
CVD 1.16 (1.01–1.34) 1.22 (1.05–1.41) 1.25 (1.05–1.50)
Non-CVD 1.01 (0.86–1.19) 1.09 (0.92–1.29) 1.09 (0.89–1.34)
All causes 1.10 (0.99–1.22) 1.16 (1.04–1.30) 1.18 (1.03–1.35)
Women
n 10,874 10,874 7,350
CVD 1.23 (0.91–1.65) 1.40 (1.03–1.89) 1.60 (1.03–2.48)
Non-CVD 0.92 (0.73–1.15) 0.99 (0.79–1.25) 1.05 (0.78–1.42)
All causes 1.03 (0.86–1.23) 1.13 (0.94–1.35) 1.18 (0.93–1.51)
Model 1: adjusted for age and cohort; model 2: model 1 plus fasting plasma glucose, BMI, total cholesterol,
smokingandhypertensionstatus;model3:model2plusfastinginsulin.GroupI,2-hplasmaglucoseFPG;
group II, 2-h plasma glucose  FPG.
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uals with normoglycemia (6,7). Thus far,
none of the studies have restricted the
comparison to individuals with normo-
glycemia, a category being considered as
having a relatively low risk for either dia-
betes (10,17) or CVD (11). Compared
with the individuals whose 2-h plasma
glucose returned to their FPG levels or
Figure1—CumulativesurvivalprobabilityfromCVD,non-CVD,andall-causedeathsderivedfromCoxregressionanalysisforgroupI(——)and
group II (– – –) in men (A) and in women (B). The analyses are adjusted for age, cohort, FPG, BMI, total cholesterol, smoking, and hypertension
status.
Normoglycemia and CVD mortality
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glucose remained higher than their FPG
(group II) were older, more obese, and
hypertensive, whereas the former had
lower fasting insulin concentrations and
comprised more smokers. These con-
founding factors did not, however, ex-
plain the difference in CVD mortality
between the two groups. Continuous sys-
tolic blood pressure instead of hyperten-
sion (yes versus no) did not change the
results at all. The higher CVD risk associ-
ated with group II compared with group I
was consistently observed in the stratiﬁed
analysis in the two FPG subgroups, sug-
gesting that the effect was independent of
the FPG levels. Moreover, the excess risk
was also observed for the difference be-
tween the FPG and the 2-h plasma glu-
cose expressed as a continuous variable.
Our study lends support to previous re-
ports that the increase in CVD risk is
graded with increasing 2-h plasma glu-
cose concentration and may extend to the
2-h plasma glucose levels below the cur-
rentdeﬁnitionforimpairedglucosetoler-
ance (4,18,19). At the low end of the
FPG distribution, the CVD risk did not
increase when the FPG concentration
increased (4,19,20).
The time that is required for the 2-h
plasma glucose concentration to return
to, or drop below, the FPG level depends
on the insulin response during the OGTT
and peripheral/hepatic insulin sensitivity
(10). Fasting hyperglycemia is predomi-
nantly associated with hepatic insulin re-
sistance and decreased ﬁrst-phase insulin
secretion (21), whereas an elevated post-
prandial glucose level is associated with
peripheral insulin resistance and impair-
mentofbothearly-andlate-phaseinsulin
responses (22). In the current study the
2-h plasma glucose concentration was
higher in group II than in group I regard-
lessoftheelevatedfastinginsulinlevelsin
group II, suggesting that insulin resis-
tance already occurred among people
with normoglycemia by the current deﬁ-
nition. Insulin resistance and the cluster-
ing of the insulin resistance with other
metabolic disorders such as obesity and
hypertensionmightbeassociatedwithin-
creased CVD mortality observed in group
II (23,24). Because insulin levels during
the OGTT were not available in the cur-
rentstudy,furtherexplorationoftheissue
is warranted.
The collaborative data analysis con-
tains some strengths. First, it provides a
large sample size and statistical power,
which could not be achieved by a single
study alone. Second, a standard OGTT
was performed in all studies to enable a
further classiﬁcation of people based on
both FPG and 2-h plasma glucose. To re-
duce the discrepancies caused by differ-
ences in study design and methods
among these studies, we have considered
study cohort as a covariate in the Cox
model and calculated a cohort-speciﬁc z
score for fasting insulin, which was used
in the data analysis. Another potential
limitation of this analysis was the rela-
tively low number of CVD events in
women. A1C was only available in two
studies: the East-West Men Study
(men  161) in Finland and the Hoorn
Study (men  798, women  974) in
the Netherlands, accounting for only
8% of the study population. The num-
ber of CVD events was also low (98 in
men and 19 in women), which did not
enablereasonabledataanalysistocheck
the effect of the A1C. In addition, some
lifestyle-related factors such as dietary
and physical activity and baseline CVD
history that may have a potential con-
tribution to the CVD were not available
for all cohorts. Further studies with
ﬁrst-ever CVD events are required to
conﬁrm the ﬁndings.
In summary, in individuals with both
FPG and 2-h plasma glucose within the
normoglycemic range, individuals whose
2-h plasma glucose concentration did not
return to their FPG level after a 75-g oral
glucose load were more insulin resistant
and had worse CVD outcomes than those
whose2-hplasmaglucosereturnedtothe
FPG level.
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